<DOC>
	<DOCNO>NCT00671736</DOCNO>
	<brief_summary>This dose-finding study investigational product Lancovutide ( Moli1901 ) exploratory phase IIb establish minimum effective dose , optimal dose , maximum safe dose . Additionally , tolerability Moli1901 shall investigate .</brief_summary>
	<brief_title>Lancovutide ( Moli1901 ) Inhalation Solution Study Adolescents Adults With Cystic Fibrosis</brief_title>
	<detailed_description>Study Moli1901-010B multi center , parallel group , placebo control , double-blind efficacy safety evaluation three different dosage schedule aerosolize Moli1901 adolescent ( 12 year age old ) , adult . Study start screen period ( visit 1 ) follow 8 week double blind comparative treatment period ( visit 2-7 ) . Thereafter , subject observed additional 4 week without treatment ( follow-up period visit 8 ) . Spirometry , pulse oximetry safety measurement perform 120 min study medication inhalation . The study conduct 30 site 9 European country .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Body mass index Confirmed diagnosis cystic fibrosis FEV1 50 % 85 % predict Oxygen saturation level measure pulse oximetry ( SpO2 ) &gt; 90 % room air Bronchial hyperresponsiveness Unstable lung function Pulmonary disease pneumonia , tuberculosis , lung cancer Acute upper respiratory tract infection within last 2 week Acute low respiratory tract infection ( require antibiotic hospitalization ) within last 4 week Pulmonary exacerbation within last 4 week Changes routine maintenance therapy within last 4 week Scheduled change inhale antibiotic regimen course study Receive plan receive treatment via `` onoff '' regimen ( e.g . Tobramycin TOBIÂ® ) ; last dose `` onoff '' treatment within last 6 week Any clinically significant liver , renal , cardiac , neurological , hematological disease ABPA colonization Burkholderia cepacia Poorly control diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>Moli1901</keyword>
	<keyword>Lancovutide</keyword>
	<keyword>2622U90</keyword>
	<keyword>duramycin</keyword>
	<keyword>lung</keyword>
</DOC>